Literature DB >> 33435990

Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer.

Xiaoqing Luo1, Shunli Peng1, Sijie Ding1, Qin Zeng1, Rong Wang1, Yueyun Ma1, ShiYu Chen1, Yanxia Wang1, Wei Wang2.   

Abstract

BACKGROUND: Serum Deprivation Protein Response (SDPR) plays an important role in formation of pulmonary alveoli. However, the functions and values of SDPR in lung cancer remain unknown. We explored prognostic value, expression pattern, and biological function of SDPR in non-small cell lung cancer (NSCLC) and KRAS-mutant lung cancers.
METHODS: SDPR expression was evaluated by quantitative real-time PCR (RT-qPCR), immunohistochemistry (IHC), and Western blot on human NSCLC cells, lung adenocarcinoma tissue array, KRAS-mutant transgenic mice, TCGA and GEO datasets. Prognostic values of SDPR were evaluated by Kaplan-Meier and Cox regression analysis. Bioinformatics implications of SDPR including SDPR-combined transcription factors (TFs) and microRNAs were predicted. In addition, correlations between SDPR, immune checkpoint molecules, and tumor infiltration models were illustrated.
RESULTS: SDPR expression was downregulated in tumor cells and tissues. Low SDPR expression was an independent factor that correlated with shorter overall survival of patients both in lung cancer and KRAS-mutant subgroups. Meanwhile, ceRNA network was constructed to clarify the regulatory and biological functions of SDPR. Negative correlations were found between SDPR and immune checkpoint molecules (PD-L1, TNFRSF18, TNFRSF9, and TDO2). Moreover, diversity immune infiltration models were observed in NSCLC with different SDPR expression and copy number variation (CNV) patterns.
CONCLUSIONS: This study elucidated regulation network of SDPR in KRAS-mutant NSCLC, and it illustrated correlations between low SDPR expression and suppressed immune system, unfolding a prognostic factor and potential target for the treatment of lung cancer, especially for KRAS-mutant NSCLC.

Entities:  

Keywords:  Immunotherapy; KRAS mutation; Lung cancer; PD-L1; SDPR (CAVIN2)

Year:  2021        PMID: 33435990      PMCID: PMC7802324          DOI: 10.1186/s12935-021-01756-8

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  36 in total

1.  Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras.

Authors:  K Scheffzek; A Lautwein; W Kabsch; M R Ahmadian; A Wittinghofer
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

Review 2.  KRAS-Mutant non-small cell lung cancer: From biology to therapy.

Authors:  Irene Ferrer; Jon Zugazagoitia; Stephan Herbertz; William John; Luis Paz-Ares; Gerald Schmid-Bindert
Journal:  Lung Cancer       Date:  2018-07-19       Impact factor: 5.705

3.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

Authors:  K Scheffzek; M R Ahmadian; W Kabsch; L Wiesmüller; A Lautwein; F Schmitz; A Wittinghofer
Journal:  Science       Date:  1997-07-18       Impact factor: 47.728

Review 4.  Treatment of ALK-positive nonsmall cell lung cancer: recent advances.

Authors:  Alesha A Thai; Benjamin J Solomon
Journal:  Curr Opin Oncol       Date:  2018-03       Impact factor: 3.645

Review 5.  Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

Authors:  Pascale Tomasini; Preet Walia; Catherine Labbe; Kevin Jao; Natasha B Leighl
Journal:  Oncologist       Date:  2016-11-02

6.  Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Authors:  Akihiko Yoshizawa; Shinji Sumiyoshi; Makoto Sonobe; Masashi Kobayashi; Masakazu Fujimoto; Fumi Kawakami; Tatsuaki Tsuruyama; William D Travis; Hiroshi Date; Hironori Haga
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

Review 7.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

8.  RET-rearranged non-small-cell lung cancer and therapeutic implications.

Authors:  Zoe Loh; Paul Mitchell; Thomas John; Surein Arulananda
Journal:  Intern Med J       Date:  2019-12       Impact factor: 2.048

9.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

Review 10.  KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.

Authors:  Helen Adderley; Fiona H Blackhall; Colin R Lindsay
Journal:  EBioMedicine       Date:  2019-03-07       Impact factor: 8.143

View more
  3 in total

1.  A novel ceRNA-immunoregulatory axis based on immune cell infiltration in ulcerative colitis-associated colorectal carcinoma by integrated weighted gene co-expression network analysis.

Authors:  Shi Yin; Xianzhe Li; Zhizhong Xiong; Minghao Xie; Longyang Jin; Huaxian Chen; Chaobin Mao; Fengxiang Zhang; Lei Lian
Journal:  BMC Gastroenterol       Date:  2022-04-15       Impact factor: 2.847

2.  Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma.

Authors:  Shun-Li Peng; Rong Wang; Yu-Ling Zhou; Wei Wei; Gui-Hua Zhong; Xiao-Tao Huang; Shuai Yang; Qiao-Dan Liu; Zhi-Gang Liu
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

3.  Comprehensive Analysis of Differentially Expressed lncRNAs miRNAs and mRNA and Their ceRNA Network of Patients With Rare-Earth Pneumoconiosis.

Authors:  Xue-Min Shi; Yu-Chao Bai; Yan-Rong Gao; Ning Bu; Hai-Yan Song; Li-Hua Huang; Yu-Hang Zhao; Su-Hua Wang
Journal:  Front Genet       Date:  2021-07-19       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.